Bristol Myers Squibb secures expanded US approval for Camzyos
The US FDA has expanded the approved indication for BMS' Camzyos to treat symptomatic oHCM in adults and paediatric patients weighing at least 30 kg.
The US FDA has expanded the approved indication for BMS' Camzyos to treat symptomatic oHCM in adults and paediatric patients weighing at least 30 kg.